TT heavy chain fragment is the C-terminal fragment of the toxin (Helting & Zwisler, 1977). It is devoid of the toxin’s enzymatic activity but contains the binding site necessary for uptake of the toxin by neurons (Roux et al., 2015; Sinha et al., 2000) and is the most immunogenic part of the toxin (Ramakrishnan et al., 2015). Fragment C contains the powerful T cell epitopes of tetanus toxin without the toxicity.
Tetanus toxoid (TT) is frequently used as a carrier protein for conjugate vaccines, in addition to being a component of the DPT vaccine. TT contains strong T cell epitopes. However, as a toxoided protein, many of the surface lysines are blocked by the toxoiding process. Furthermore, TT is not a uniform product, since each manufacturer has its own specific toxoiding and purification process. Tetanus toxoid also tends to aggregate with age and is not generally affordable in the quantities needed for research and early clinical work. Recombinant TT combines the advantages of the toxoid with the reproducibility of a recombinant protein.
Source:Recombinant protein corresponding to carboxyl fragment of Tetanus Toxoid Heavy Chain, expressed in E. coli.
Storage and Stability:Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
Source Antigen：Recombinant, E. coli
Grade：Highly Purified
Purity：≥98% (SEC HPLC)
Form：Supplied as a liquid in 20mM HEPES, pH 7.2, l00mM sodium chloride, 10% glycerol.
